# Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis

> **NCT02467504** · PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 47 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** hrIL-2 active
- **DRUG:** hrIL-2 placebo
- **DRUG:** MTX
- **DRUG:** Folic Acid
- **DRUG:** Loxoprofen

## Key facts

- **NCT ID:** NCT02467504
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2017-01-15
- **Final completion:** 2017-08-31
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02467504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02467504, "Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02467504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*